237 related articles for article (PubMed ID: 16908132)
1. Numerous high-risk epithelial lesions in familial breast cancer.
Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
[TBL] [Abstract][Full Text] [Related]
2. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
3. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.
Kauff ND; Brogi E; Scheuer L; Pathak DR; Borgen PI; Hudis CA; Offit K; Robson ME
Cancer; 2003 Apr; 97(7):1601-8. PubMed ID: 12655515
[TBL] [Abstract][Full Text] [Related]
4. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
5. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
6. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
7. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.
Isern AE; Loman N; Malina J; Olsson H; Ringberg A
Eur J Surg Oncol; 2008 Oct; 34(10):1148-54. PubMed ID: 18434071
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Leunen K; Drijkoningen M; Neven P; Christiaens MR; Van Ongeval C; Legius E; Amant F; Berteloot P; Vergote I
Breast Cancer Res Treat; 2008 Jan; 107(1):79-86. PubMed ID: 17431765
[TBL] [Abstract][Full Text] [Related]
9. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
10. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
11. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
12. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
13. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.
Rueth NM; McMahon M; Arrington AK; Swenson K; Leach J; Tuttle TM
Ann Surg Oncol; 2011 Sep; 18(9):2515-20. PubMed ID: 21424371
[TBL] [Abstract][Full Text] [Related]
14. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk.
Kurian AW; Mills MA; Jaffee M; Sigal BM; Chun NM; Kingham KE; Collins LC; Nowels KW; Plevritis SK; Garber JE; Ford JM; Hartman AR
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1082-9. PubMed ID: 15894656
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
17. Screening and follow-up of the patient at high risk for breast cancer.
Willey SC; Cocilovo C
Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
[TBL] [Abstract][Full Text] [Related]
18. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
19. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
20. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
